12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

Elan withdrew an application in the EU to expand the label of Tysabri natalizumab to include first-line treatment of relapsing-remitting multiple sclerosis (RRMS) that is not highly active in patients who are anti-JC virus (JCV) antibody-negative. According to EMA's CHMP, the company withdrew the application because "the additional data it had to address the...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >